Idarucizumab for dabigatran overdose

Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers

(2016) Stephan Glund et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH

(2016) J. H. Levy et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II

(2015) Menno V. Huisman et al.   AMERICAN JOURNAL OF MEDICINE

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial

(2015) Stephan Glund et al.   LANCET

Idarucizumab for Dabigatran Reversal

(2015) Charles V. Pollack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab

(2015) Markus Honickel et al.   THROMBOSIS AND HAEMOSTASIS

A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran

(2015) Viktoria Moschetti et al.   THROMBOSIS AND HAEMOSTASIS

Extracorporeal Therapy for Dabigatran Removal in the Treatment of Acute Bleeding: A Single Center Experience

(2013) T. Singh et al.   Clinical Journal of the American Society of Nephrology

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

(2013) Hein Heidbuchel et al.   EUROPACE

The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients

(2013) Paul A. Reilly et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors

(2012) Scott Kaatz et al.   AMERICAN JOURNAL OF HEMATOLOGY

Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate

(2010) Joachim Stangier et al.   CLINICAL PHARMACOKINETICS